(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
A phase 2 trial of Darovasertib in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting.
Overview
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma is a phase 2 interventional study registered as NCT05907954 by IDEAYA Biosciences, with 160 participants planned, started 2023-07-03 and due to reach its primary completion in 2027-04-30. Interventions recorded: Darovasertib. Conditions listed: Uveal Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialNeoadjuvant Darovasertib in Primary Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
- TrialStudy of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
- TrialStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma, Melanoma.
- TrialIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma, Melanoma.
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma, Melanoma.
- TrialDual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Shares Uveal melanoma, Melanoma.